Torcetrapib, also known as CP-529,414 was a drug being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease. Its development was halted in 2006 when phase III studies showed excessive all-cause mortality in the treatment group receiving a combination of atorvastatin (Lipitor) and torcetrapib. Torcetrapib acts (as a CETP inhibitor) by inhibiting cholesterylester transfer protein (CETP), which normally transfers cholesterol from HDL cholesterol to very low density or low density lipoproteins (VLDL or LDL). Inhibition of this process results in higher HDL levels and reduces LDL levels.
Properties:
Appearance & Physical State: lipid
Density: 1.42g/cm3
Melting Point: 54-58ºC
Boiling Point: 504.8ºC at 760mmHg
Flash Point: 259.1ºC
Refractive Index: 1.511
Vapor Pressure: 2.58E-10mmHg at 25°C